Egle Therapeutics
Latest round
- Series A
Last raised
- Oct 2021
Total raised
- $17M
Investors
- 6
About Egle Therapeutics
Egle Therapeutics SAS, based in Paris, France, is a biotechnology company focused on developing innovative therapies that engage regulatory T cells to treat cancer and autoimmune diseases. Founded in 2020 in Paris, France, Egle Therapeutics specializes in therapies targeting regulatory T cells (Tregs). Egle Therapeutics specializes in the development of innovative therapies targeting regulatory T cells (Tregs) for cancer and autoimmune diseases. Their lead products include EGL-001, currently in clinical trials for oncology (NCT06622486), and EGL-003, which has completed IND-enabling studies and plans to enter Phase I trials in 2025. The company employs a proprietary discovery platform that utilizes multi-omics analyses and bioinformatics to identify therapeutic Treg targets, focusing on markets in North America and Europe. This structure also includes milestone payments and royalties on future product sales as the company advances its lead products.
Who invested in Egle Therapeutics
6 investors across 1 round
See all investors in Egle Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 12, 2021
Amount
$17M
Investors
Questions about Egle Therapeutics
Who invested in Egle Therapeutics?
Egle Therapeutics has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Egle Therapeutics raised?
Egle Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Egle Therapeutics last raise money?
Egle Therapeutics's most recent round on record is a Series A, in Oct 2021.
What does Egle Therapeutics do?
Egle Therapeutics SAS, based in Paris, France, is a biotechnology company focused on developing innovative therapies that engage regulatory T cells to treat cancer and autoimmune diseases.
Where is Egle Therapeutics headquartered?
Egle Therapeutics is headquartered in Suresnes, France.
Which VCs invest in companies like Egle Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Egle Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Egle Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.